Kornimate/medical-research-clean huggingface dataset:
a correlation study of cognitive function in patients with depression

Conditions: Depression

Summary: many studies have shown that patients with depression had weak brain region connections and low levels of activation of the prefrontal lobe when brain activity was active and that patients with depression have a negative attentional bias, and the patient's abnormal attentional allocation may stem from a loss of attention avoidance of negative cues and a loss of attention preference for positive cues. here use the near-infrared, eye movement to evaluate the cognitive function in patients with depression. the purpose of the study is to explore the correlation between depressed symptom and cognition function among the depression patients and the difference between first-onset of depressed patients and those is recurrent.

this study will comprise 200 patients with depression disorder. all participants will be assessed and clinically examined at baseline, and all patients are encouraged to follow up at week 12. baseline assessments will include demographics, menstrual records for female, comprehensive medical history, physical examination, near-infrared, eye movement and laboratory work (e.g., hormones). the follow-up of patients will include laboratory work, near-infrared, eye movement. clinical symptoms will be assessed by hamd-17,hamiltonanxietyscale, and young mania rating scale. the cognitive function will be assessed at baseline and week 12 .the primary outcomes will be the near-infrared , eye movement . secondary outcomes will include overall psychiatric symptomatology, cognitive function, and other biological data.

Eligibility criteria:
inclusion criteria: 1. meets the dsm-5 (diagnostic and statistical manual of mental disorders, 5th edition) diagnostic criteria for depressive disorders 2. age 18-60 years, gender aside, at least 1 guardian to monitor the patient for 2 months 3. obtain informed consent from patients and guardians, sign informed consent forms, and be able to comply with planned visits, laboratory tests, and other research procedures 4. it is expected that there will be no problems such as relocation of residence, inconvenience of transportation, and difficulty in obtaining medical treatment throughout the study process 5. there is sufficient audiovisual level to complete the necessary examinations for the study exclusion criteria: 1. presence of any other medical disorder affecting reproductive endocrine function; abusers of psychoactive substances or substances such as alcohol 2. people with severe physical disabilities who are unable to complete follow-up 3. have been diagnosed or have had other severe psychiatric disorders that meet the diagnostic criteria for dsm-5, mental retardation, dementia, severe cognitive dysfunction, etc 4. previously or currently suffering from any major physical disease, neurological disorder, brain trauma, etc. that affect the structure or function of the brain 5. suicidal or uncooperative 6. pregnant or lactating women 7. there is significant anxiety, hama ≥ 21 points

Keywords: depression cognition function near-infrared eye movement
clinical evaluation gastrointestinal motility with pillcam

Conditions: Gastrointestinal Motility

Summary: the purpose of this study is to evaluate the clinical usefulness of a video camera pill (pillcam) in assessing intestinal function in the small intestines of patients. it is believed that the condition of the subjects digestive system can have a large impact on their overall physical health. therefore, the investigators would like to assess whether using the pill device helps to determine any functional problems in patients in the icu. the investigators are studying icu patients because any change in their condition can have a large impact on their recovery. the same device will be used in healthy subjects scheduled for elective ambulatory surgery.


Eligibility criteria:
inclusion criteria: * mild-to-moderate brain injury patients who suffered from traumatic or non-traumatic intracranial hemorrhage * admitted to an intensive care unit (icu) * needed an enteral tube placed for feeding * control (ambulatory) group consisted of outpatients with no history of major abdominal surgery exclusion criteria: * younger than 18 years * suffered multiple injuries (especially abdominal trauma or inflammatory bowel disease) * had a history of complicated or unknown abdominal surgery * presented with clinical evidence of ileus or suspected obstruction * patients with a pacemaker

Keywords: critical care endoscopy, video capsule nutrition, enteral
rehabilitation outcomes study

Conditions: Cancer; Malignant Tumor

Summary: this pilot health services interventional study aims to prospectively assess the effectiveness of a pre-treatment rehabilitation (prehabilitation) program across a diverse cohort of adult cancer patients via a randomized pilot trial. upon screening and identification of high-risk features through a central navigation process, patients referred to oncology clinics will be approached to participate in tailored prehabilitation interventions. the study will track and analyze functional outcomes and quality of life aiming to demonstrate the comprehensive benefits of prehabilitation on the cancer treatment continuum. we hypothesize that this referral program is feasible and that those randomized to the intervention arm will have superior functional outcomes and global health-related quality of life. the rationale for this study is anchored in the urgent need to optimize the cancer care trajectory for high-risk patients whose treatment outcomes and quality of life are jeopardized by the multifaceted challenges of their disease. while prehabilitation has shown potential to mitigate these adverse effects, the optimal methods for identifying and connecting these high-risk individuals to appropriate prehabilitation resources remain underexplored. this study, with its systematic approach to enrolling a diverse adult cancer population, endeavors to investigate not only the benefits of prehabilitation interventions but also the effectiveness of a targeted referral process. by doing so, it aims to uncover novel strategies for efficiently allocating prehabilitation resources, thereby enhancing the precision and impact of supportive cancer care.


Eligibility criteria:
inclusion criteria: * written informed consent obtained to participate in the study and hipaa authorization for the release of personal health information. * subjects are willing and able to comply with study procedures based on the judgement of the investigator. * age ≥ 18 years at the time of consent. * the subject has been screened by the central oncology navigation program and referred to cancer care at the university of north carolina medical center. * answer "yes" to at least one of the following screening questions: 1. does your health interfere with any of your activities of daily living (adls)? 2. have you fallen, or do you feel unsteady while standing or walking? 3. do you use durable medical equipment (dme)? 4. are you interested in increasing the amount you exercise? exclusion criteria: * inability to read and understand the english language. * psychological or other disability resulting in the inability to provide informed consent. * unstable medical comorbidity that precludes safe participation in an exercise program, in the judgment of the clinical investigator. * prisoners and other institutionalized individuals.

Keywords: rehabilitation
a study of the safety of rabeprazole administered to adults with gastroesophageal reflux disease (gerd)

Conditions: Gastroesophageal Reflux; Heartburn

Summary: the purpose of the study is to confirm the safety and effectiveness of rabeprazole in the treatment of patients with erosive or ulcerative gastroesophageal reflux disease (gerd) in routine primary health care.

gastroesophageal reflux can result in mild to severe symptoms in some persons. heartburn, a burning sensation or discomfort rising behind the breastbone, is a common symptom. gastroesophageal reflux disease (gerd) can be described as a condition with clearly identified clinical symptoms or the change in tissue structure that results from the reflux of contents from the stomach or small intestine into the esophagus. this is a study to confirm the safety and effectiveness of rabeprazole in the treatment of patients with gerd in routine primary health care. the study has two phases. patients will receive treatment with rabeprazole tablets once daily for 8 weeks. in the second phase, patients will be monitored by their physician for a follow up period to end of study (12 months). safety assessments include the incidence of adverse events throughout the treatment and follow up phases, and physical examination and laboratory tests at end of treatment and after 4 months. assessments of effectiveness include the degree of relief of symptoms at beginning and end of treatment and at specific intervals during follow up. the study hypothesis is that rabeprazole is well-tolerated with long term treatment of patients with gerd in routine primary health care. rabeprazole tablet (20 milligrams\[mg\]) once daily in the morning for 8 weeks. dose may be increased to 2 tablets daily (40 mg maximum) at investigator's discretion.

Eligibility criteria:
inclusion criteria: * patients with symptoms of erosive or ulcerative gastroesophageal reflux disease (gerd) during at least a period of 3 months prior to study initiation and symptoms of gerd for at least 3 days per week within the 2 weeks prior to study initiation. the symptoms of erosive or ulcerative gastroesophageal reflux disease includes the following: heartburn, aching behind the breastbone, a need for antacids, and difficulty in swallowing. patients with evidence by endoscopy of erosive or ulcerative gastroesophageal reflux disease with no barret-type tissue transformation. exclusion criteria: * no narrowing or inflammation of the esophagus * no known gastro-duodenal ulcer * no infections (other than h. pylori), inflammations or hemorrhage of the stomach, small or large intestine * no prior surgery of the stomach or intestine * no known history of primary kinetic disorders of the esophagus, other than gerd * no history of enlarged veins of the esophagus or stomach * no pregnant or nursing females, or those lacking adequate contraception.

Keywords: gastroesophageal reflux heartburn rabeprazole gerd anti-ulcer agents proton pump inhibitor
review of trend in incidence and characteristics of hospital-acquired acute kidney injury in hospital selayang

Conditions: Acute Kidney Injury; Acute Renal Failure; Kidney Failure, Acute; Hospital Acquired Condition

Summary: this retrospective cohort study aims to investigate the incidence, risk factors and outcomes of hospital-acquired acute kidney injury in hospital selayang, a tertiary hospital at malaysia, over 15 years.

this is a retrospective cohort study involving 5-yearly trend from 2002 to 2017 for analysis. laboratory serum creatinine (scr) results of all patients admitted during study period will be retrieved from the hospital laboratory information system. a preliminary screening list will be generated by using stata program from the scr results. the nephrologist will then determine ha-aki and ca-aki as per inclusion and exclusion criteria. data collectors will collect all relevant data from these patients.

Eligibility criteria:
inclusion criteria: * adult admissions to hospital selayang from * 1st july 2001 to 30th june 2002 * 1st july 2006 to 30th june 2007 * 1st july 2011 to 30th june 2012 * 1st july 2016 to 30th june 2017 exclusion criteria: * end stage renal failure and on renal replacement therapy (hemodialysis, peritoneal dialysis or renal transplant)

Keywords: acute kidney injury hospital-acquired acute kidney injury community-acquired acute kidney injury acute renal failure
pilot study to improve care coordination

Conditions: Chronic Illness

Summary: the purpose of this study is 1) to learn how va patients can help share their health information between their va providers and providers outside the va and 2) if sharing this information is useful to providers and improves care received.

recent studies estimate that 43 to 75% of veterans also receive care from non-va providers (dual use). dual use is a concern because splitting care between two or more health systems and multiple providers may result in poor coordination of services and a loss of continuity -ultimately putting the patient at increased risk for poor outcomes. addressing dual use in veterans is an issue of care coordination. one component of care coordination is information sharing, which often relies on the patient to share information between systems/providers. veterans registered in my healthevet with premium account status have access to download and print a va health summary (va ccd). this health summary can be shared with non-va providers to inform them about recent va care. this pilot randomized controlled trial will compare usual care to an intervention which aims to improve care coordination for dual use veterans by educating them about the use of information technology to share health information and informing their providers about the extent and nature of care from other health care systems. methods: dual use veterans with at least one chronic health condition and both an upcoming va and non-va appointments within the study time frame will be eligible to participate. veterans will be randomized to the intervention or usual care. veterans in the intervention group will be trained on use of my healthevet and their community patient portal (if applicable) to access summary health information to share with providers. in addition, he/she will create a document that lists all members of their health care team. all participants will be asked to take a provider evaluation packet each provider visit (va and non-va). after the visit, a phone call will be scheduled with the veteran to ask about the appointment and medical records from the appointment will be obtained. outcomes: the main outcomes will be related to patient perceived continuity of care, provider relational coordination survey, medication concordance, and medical laboratory test duplication. pre and post scores on the patient activation measures will also be explored.

Eligibility criteria:
inclusion criteria: va patient * receives health care from va and non-va provider * diagnosed with a chronic health condition * prescribed 5 or more medications * upcoming va and non-va appointments within the study time frame * registered or willing to become registered with my healthevet * access to a computer with internet, phone, and a printer. * english speaking va or non-va providers: provide care to a stuy participant exclusion criteria: * previously shared health data with a provider via their my healthevet or local provider patient portal * no scheduled va or non-va appointments

Keywords: continuity of patient care health records, personal veterans patient participation chronic disease
a study assessing 13-valent pneumococcal conjugate vaccine in healthy chinese infants and young children

Conditions: Pneumococcal Infections; Pneumococcal Conjugate Vaccine

Summary: the purpose of this study is to assess the safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in chinese infant and young children.


Eligibility criteria:
inclusion criteria: * evidence of a personally signed and dated icd indicating that the parent(s)/legal guardian has been informed of all pertinent aspects of the study. * aged 6 weeks (42 days) to \<6 years at the time of consent. * healthy infants and children as determined by medical history, physical examination, and judgment of the investigator. exclusion criteria: * participation in other studies involving investigational drug(s)/vaccine(s) since birth (cohort 1 only) or in the 6 months prior to study entry (cohorts 2, 3, and 4) and/or during study participation. * other acute or chronic medical or psychiatric condition, including recent laboratory abnormality, that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. * vaccination with licensed or investigational pneumococcal vaccine. * previous vaccination with licensed or investigational hib vaccine.
single versus double kirschner wires for intramedullary fixation of metacarpal v fractures

Conditions: Fracture of Metacarpal Bone

Summary: metacarpal v fractures are injuries of the upper extremities. they occur frequently, primarily in young adults.these fractures are caused by falling on the fist, sports accidents and direct or indirect forces. surgical intervention is necessary for fractures with a strong palmar angulation of the metacarpal bone or rotational deformity of the small finger. due to the absence of guideline recommendations decisions about therapy are made taking into account logistical aspects, available hardware, individual expertise and preferences. the objective of the study is to compare the advantages and disadvantages of single versus double kirschner wires for intramedullary fixation of metacarpal v fractures in order to standardize national therapy procedures. primary hypothesis: in the surgical therapy of the dislocated and/or rotational deformed metacarpal v neck fracture, osteosynthesis with a single kirschner wire is not inferior to osteosynthesis with a double kirschner wire with regard to the functional outcome after 6 month, as measured with the disabilities of the arm, shoulder and hands score (dash).


Eligibility criteria:
inclusion criteria: * patients ≥18 years with a metacarpal v neck fracture with a palmar angulation and/or shortening and /or rotational deformity as determined on radiological diagnosis * trauma within 10 days before appearing in the study centre * no specific medical treatment before * ability to fully understand the character and implications of the clinical trial * written or oral (in case of an injury of the dominant hand, if so attested by witnesses)consent exclusion criteria: * indications for conservative therapy * patient is not suitable for anaesthesia * other physical conditions or characteristics which made surgical interventions inappropriate or to risky (e.g. open fractures, polytrauma, pregnancy, acute infections, pathological fractures) * prior participation in this study (e.g. injury of the contralateral hand) or participation in other interventional studies with the same objective * physical or mental diseases which makes the consequent participation in diagnostic, therapy and the follow-up-examinations unlikely * lacking language skills

Keywords: metacarpal v fractures single kirschner wires double kirschner wires
a 2-year clinical impact of bulk-fill low-viscosity resin composite liners in class ii restorations.

Conditions: Dental Caries Class II

Summary: this randomized clinical trial evaluated the clinical performance of class ii resin composite restorations using bulk-fill high-viscosity ormocer versus methacrylate-based with or without a thin layer of bulk-fill low-viscosity (flowable) resin composite liners (blrc) over 2 years. the null hypotheses in the study were as follows: (1) different types of matrix structures (ormocer vs. methacrylate) have no effect on the marginal integrity of restorations; (2) a layer of bulk-fill resin compo-site liner of the same category would not affect the marginal or internal adaptation of restorations.

the study was designed following the consolidated standards of reporting trials (consort) statement. approvement by the local ethics committee of mansoura university code register was taken code m 11120520. the patients were selected as they searched for treatment in the conservative dentistry department outpatient clinic, in the faculty of dentistry, mansoura university. a group of 30 patients 21 females and 9 males was chosen from among 92 participants after careful consideration of the inclusion and exclusion criteria. the sample size estimate was made based on the clinical success rate of posterior class ii composite restorations observed in a prior study (97.5% at 24 months). the sample size needed per group was 23 teeth using a significance level of 0.05, power of 80%, and equivalency limit of 15%. a total of 30 patients were chosen, for a total of 120 restorations (30 for each group) after taking potential dropouts into account. to ensure adherence of the participants to the study, all volunteers underwent complete dental treatment and periodic follow-ups. the volunteers were contacted by telephone, whatsapp message, facebook, and e-mail for the assessments. four attempts, including visits to the schools, were made to contact a volunteer before he/she was considered a "loss." both participants and examiners were blind to the interventions. an inter-examiner and intra-examiner agreement of at least 90% was requested before the beginning of the evaluation. clinical evaluation was performed one week after finishing and polishing (baseline), after 6 months, 12 months, 18 months, and 24 months using the world dental federation (fdi) criteria.

Eligibility criteria:
inclusion criteria: * patients having at least 4 posterior teeth with moderate occlusal-proximal carious lesions. * patients ranging in age from 18 to 30 years. * patients with normal occlusion. exclusion criteria: general exclusion criteria: * patients having severe chronic periodontitis. * patients with orthodontic appliances. * abnormal occlusion, parafunctional habits. * allergy to any of the materials used in the study. specific teeth exclusion criteria * teeth with irreversible pulpitis or non-vital. * fractured or cracked teeth. * previously restored teeth. * cavities with isthmus larger than intercuspal distance. * teeth with deep sub-gingival cavity margins.
study looking at biomarkers in ovarian cancer

Conditions: Gynecologic Cancer

Summary: this is a sample study that will collect biological samples (blood, tumor tissue, ascites, and/or other fluids) from gynecological cancer patients for biomarker research. in addition, the results of the testing done on the samples will be given to the participant's treating physician who may use the information to guide treatment decisions.


Eligibility criteria:
inclusion criteria: * histological diagnosis of stage iii or iv high grade serous ovarian, tubal or primary peritoneal cancer. * must be 18 years of age or older. * eastern cooperative oncology group (ecog) performance status 0-1. * have a life expectancy greater than or equal to 6 months. * able to provide adequate informed consent. * willing to undergo blood or fluid collection and tumour biopsy * patients enrolled at the time of surgery must agree to have part of their tumour used for the purpose of the study. * archival tissue must be available for patients that are enrolled at the time of progression. exclusion criteria: * must not have early stage (i and ii) high grade serous, tubal or primary peritoneal cancer. * must not have other tumour histology other than high grade serous. * must not have contraindication to tumour biopsy and/or blood sampling.